Tag:

Regeneron

Latest Headlines

Latest Headlines

Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion

Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.

New use for Bayer's Eylea in EU gives it more market power against Novartis' Lucentis

The European Commission has approved Bayer's Eylea (aflibercept) for the treatment of diabetic macular edema, the most common cause of vision loss among people with diabetes.

Regeneron hits the gas on R&D, pouring cash into a blockbuster pipeline

Regeneron has again dialed up its R&D budget, spending more and more on a slew of late-stage assets that promise to line its pockets and an emerging crop of early drugs the Big Biotech believes can beat a path to blockbuster status.

Regeneron sales soar in Q2 on growing Eylea demand--what's new?

After a brief hiatus, Regeneron is back to steamrolling analysts' expectations. Tuesday, the drugmaker reported second-quarter results that topped Wall Street's projections, thanks once again to growing demand for macular degeneration treatment Eylea.

Sanofi, Regeneron pay $67M for a shortcut in the blockbuster PCSK9 race with Amgen

Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening that they had picked up a priority review voucher BioMarin had won for a recent rare disease drug approval, paying $67.5 million for the regulatory shortcut. They'll split the cost and share in the benefit, shaving four months off the regulatory review time for alirocumab.

Sanofi, Regeneron prep their PCSK9 cardio contender for FDA review after PhIII sweep

Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients' bad cholesterol.

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.

Sanofi bumps stake in Regeneron to 22.5%

Sanofi CEO Chris Viehbacher is often pressed to answer why he doesn't just buy Regeneron, a biotech outfit closely bonded with Big Pharma on several important development initiatives.

Big biotech booms while pharma payrolls wither

The past 10 years have seen Big Pharma repeatedly cannibalize itself via megamerger, trimming its ranks through waves of layoffs and a dogged pursuit of efficiency. But Big Biotech, the emerging middle class of not-quite giants, has more than made up for those cuts, essentially doubling to add more than 130,000 workers since 2003, according to EvaluatePharma.

Sanofi, Regeneron add positive PhIII data on key RA drug

Sanofi and its close development partner Regeneron added some positive year-long results to the promising Phase III rheumatoid arthritis data that they've been gathering on sarilumab, an antibody that is billed as one of the pharma giant's top late-stage drug prospects.